Dr. Tyler Yu is the co-founder and Chief Technology Officer of Nutshell Therapeutics. He is a seasoned veteran in drug research and discovery, with over 20 years of working experience. He has published over 40 research patents and peer-reviewed scientific papers. After receiving his PhD from the University of Massachusetts, Amherst, Dr. Yu worked as a principal investigator in R&D at Dow Chemical, Abbvie, and Novartis. In 2008, Dr. Yu returned to Shanghai to participate in the new Novartis Research Center (China), where he established the computer-aided drug design/chemical information/hit-finding platform. As a co-leader, Dr. Yu was involved in a number of drug discovery projects that are currently in clinical stage development. These include next generation inhibitors designed for mature targets and First in Class (FIC) small molecule drugs designed for novel targets. Since 2018, Dr. Yu was Director of Innovative Technology and Academic Partnering at Novartis China, responsible for exploring cutting-edge technologies such as AI (Artificial Intelligence), PROTAG (Proteolysis Targeting chimera), and DEL (DNA Encode Library)